The acute and chronic effects of gut neuropeptides on intracranial pressure regulation

niversity of Birmingham0 个研究点目标入组 15 人开始时间: 2017年7月18日最近更新: 2024年8月19日

适应症

试验速览

2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36320018/ Evaluation of telemetric intracranial pressure monitoring (added 03/11/2022) 2022 Preprint results in https://doi.org/10.1101/2022.05.24.22275518 Exenatide results (added 07/11/2022) 2022 Abstract results in https://doi.org/10.1186/s10194-022-01527-4 (added 05/08/2024) 2020 Other publications in https://pubmed.ncbi.nlm.nih.gov/33090189/ (added 05/08/2024) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/38487358/ Sub-study (added 05/08/2024)

•2. Aged 18-60 years old
•3. Diagnosed with IIH by the modified Dandy criteria
•4. Active disease (papilloedema Frisen grade greater than 1)
•5. Significantly raised ICP (greater than 25cm CSF)
•6. No evidence of venous sinus thrombosis (documented normal MR Venogram of CT Venogram)
•6. Able to provide informed consent

•1. Aged less than 18 or older than 60 years
•2. Pregnant or trying to conceive
•3. Significant co-morbidity, such that in the opinion of the investigator it would not be in the participant’s best interest to participate in the trial
•4. Addison’s or Cushing’s disease
•5. Functioning CSF shunt/stent or optic nerve sheath fenestration
•6. Currently using GLP-1 agonist or DPP-4 inhibitor
•7. Surgical contra-indication
•8. Concomitant therapy with acetazolomide, topiramate or diuretics (this can be discontinued 1 month prior to enrolment)
•9. Inability to give informed consent e.g. due to cognitive impairment

发起方